Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

About this update from Kiora Pharmaceuticals, Inc.

[{"type":"text","content":"Encinitas, California--(Newsfile Corp. - May 8, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today reported financial results for the first quarter ended March 31, 2026, and provided an update on its clinical pipeline of small molecules for the treatment of retinal diseases.","length":275,"tagName":"p"},{"type":"text","content":"First Quarter 2026 and Recent Highlights","length":40,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Enrollment in the Phase 2 ABACUS-2 study of KIO-301 remains very active, with expansion of clinical trial sites to accommodate the strong patient demand to participate in the trial","length":180,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Publication of ABACUS-1 clinical trial results in Nature Medicine, providing external validation of KIO-301's potential for vision restoration in patients with late-stage retinitis pigmentosa","length":195,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Continued progress in the Phase 2 KLARITY study of KIO-104, with an upcoming, pre-defined safety review to support advancement to the next dose level","length":149,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Kiora has an operational runway into late 2028, well beyond the anticipated clinical data readouts from both ongoing clinical trials","length":132,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Subsequent to the end of the quarter, Kiora executed a strategic equity financing, led by Perceptive Advisors that further strengthens the balance sheet","length":152,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":808,"olType":false},{"type":"text","content":""We are encouraged by the continued progress across both of our clinical programs, including the strong momentum we are seeing with KIO-301 enrollment," said Brian Strem, Ph.D., President and Chief Executive Officer of Kiora. "Recruitment in our ABACUS-2 study continues to advance, with close to 50% already completed, ongoing or scheduled to be followed by dose escalation of the drug in our second cohort of patients. We are seeing significant interest from both patients and physicians. This partially reflects the high unmet need within this rare disease community and the close-knit network of treating specialists. Importantly, th...

More updates from Kiora Pharmaceuticals, Inc.